公开(公告)号：US20230111095A1

公开(公告)日：2023-04-13

申请号：US17769607

申请日：2020-09-25

申请人： Cansino Biologics Inc.

发明人： Haomeng WANG ,  Qiaoling YAN ,  Shoubai CHAO ,  Huhua MAO ,  Tao ZHU

IPC分类号： A61K39/385 ,  A61P31/04 ,  A61K39/09

摘要： The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.

公开(公告)号：US20230183298A1

公开(公告)日：2023-06-15

申请号：US18150496

申请日：2023-01-05

申请人： CANSINO BIOLOGICS INC.

发明人： Haomeng WANG ,  Zhihong YAN ,  Qiaoling YAN ,  Juan SHAO ,  Jianming SHI ,  Xiuwen SUI ,  Junqiang LI ,  Tao ZHU

IPC分类号： C07K14/22 ,  A61K39/116

CPC分类号： C07K14/22 ,  A61K39/116

摘要： Provided are a protein antigen subjected to site-directed mutation and site-directed modification, and a method for site-directed mutation and site-directed modification of the protein antigen. The method comprises: site-directedly introducing an unnatural amino acid into a specific site of the protein antigen by genetic codon expansion technique; and performing site-directed modification with the protein antigen by the unnatural amino acid and a modifier, wherein the modifier is a receptor agonist such as tripalmitoyl-S-glyceryl cysteine and monophosphoryl lipid A. Further provided is use of the protein antigen subjected to site-directed mutation and site-directed modification, such as use as a vaccine.